Pamela L Zeitlin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3697554/publications.pdf

Version: 2024-02-01

119 papers	6,894 citations	61984 43 h-index	60623 81 g-index
123 all docs	123 docs citations	123 times ranked	6100 citing authors

#	Article	IF	Citations
1	The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions. Journal of Allergy and Clinical Immunology, 2022, 149, 488-516.e9.	2.9	24
2	Receptor-mediated activation of CFTR via prostaglandin signaling pathways in the airway. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2022, 322, L305-L314.	2.9	6
3	The Changing Face of Cystic Fibrosis: An Update for Anesthesiologists. Anesthesia and Analgesia, 2022, Publish Ahead of Print, .	2.2	3
4	Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro. Journal of Cystic Fibrosis, 2022, 21, 637-643.	0.7	2
5	IL-13â€“programmed airway tuft cells produce PGE2, which promotes CFTR-dependent mucociliary function. JCI Insight, 2022, 7, .	5.0	19
6	Downregulation of epithelial sodium channel (ENaC) activity in human airway epithelia after low temperature incubation. BMJ Open Respiratory Research, 2021, 8, e000861.	3.0	3
7	Characterizing mucociliary clearance in young children with cystic fibrosis. Pediatric Research, 2021, , .	2.3	1
8	Expanding CFTR Modulator Testing to Carriers of CFTR Variants. Annals of the American Thoracic Society, 2021, 18, 1776-1779.	3.2	0
9	Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment. Scientific Reports, 2021, 11, 19810.	3.3	42
10	Measurements of spontaneous CFTR-mediated ion transport without acute channel activation in airway epithelial cultures after modulator exposure. Scientific Reports, 2021, 11, 22616.	3.3	2
11	Impact of sleep opportunity on asthma outcomes in adolescents. Sleep Medicine, 2020, 65, 134-141.	1.6	14
12	Effect of apical chloride concentration on the measurement of responses to CFTR modulation in airway epithelia cultured from nasal brushings. Physiological Reports, 2020, 8, e14603.	1.7	8
13	Changes in mucociliary clearance over time in children with cystic fibrosis. Pediatric Pulmonology, 2020, 55, 2307-2314.	2.0	6
14	Cystic fibrosis transmembrane conductance regulator function, not TAS2R38 gene haplotypes, predict sinus surgery in children and young adults with cystic fibrosis. International Forum of Allergy and Rhinology, 2020, 10, 748-754.	2.8	7
15	Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial. Journal of Asthma and Allergy, 2018, Volume 11, 181-192.	3.4	33
16	Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR. JCI Insight, 2018, 3, .	5.0	56
17	Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. Journal of Cystic Fibrosis, 2017, 16, 371-379.	0.7	46
18	Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding. Annals of the American Thoracic Society, 2017, 14, 220-229.	3.2	22

#	Article	IF	Citations
19	Clinical Phenotypes and Genotypic Spectrum of Cystic Fibrosis inÂChineseÂChildren. Journal of Pediatrics, 2016, 171, 269-276.e1.	1.8	34
20	Direct interactions between ENaC gamma subunit and ClCN2 in cystic fibrosis epithelial cells. Physiological Reports, 2015, 3, e12264.	1.7	3
21	Interference with Ubiquitination in CFTR Modifies Stability of Core Glycosylated and Cell Surface Pools. Molecular and Cellular Biology, 2014, 34, 2554-2565.	2.3	13
22	Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respiratory Medicine,the, 2014, 2, 539-547.	10.7	301
23	Dual activation of CFTR and CLCN2 by lubiprostone in murine nasal epithelia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2013, 304, L324-L331.	2.9	25
24	Prevention of ubiquitination at lysines in the N tail, R, ICL4, and NBD2 domains disrupts CFTR trafficking and immune response. FASEB Journal, 2013, 27, 782.3.	0.5	0
25	Genetics and Pathophysiology of Cystic Fibrosis. , 2012, , 753-762.		2
26	Antibody Microarrays: Analysis of Cystic Fibrosis. Methods in Molecular Biology, 2012, 823, 179-200.	0.9	7
27	Cystic Fibrosis and Sinusitis in Children. Otolaryngology - Head and Neck Surgery, 2011, 145, 146-153.	1.9	27
28	N-acetylcysteine Enhances Cystic Fibrosis Sputum Penetration and Airway Gene Transfer by Highly Compacted DNA Nanoparticles. Molecular Therapy, 2011, 19, 1981-1989.	8.2	80
29	Etiology of Bronchopulmonary Dysplasia: Before Birth. Pediatric, Allergy, Immunology, and Pulmonology, 2011, 24, 21-25.	0.8	2
30	Elevated Serum IL-8 Levels in Ataxia Telangiectasia. Journal of Pediatrics, 2010, 156, 682-684.e1.	1.8	40
31	NHLBI training workshop report: The vanishing pediatric pulmonary investigator and recommendations for recovery. Pediatric Pulmonology, 2010, 45, 25-33.	2.0	12
32	Description of a Standardized Nutrition Classification Plan and its Relation to Nutritional Outcomes in Children with Cystic Fibrosis. Journal of Pediatric Psychology, 2010, 35, 6-13.	2.1	21
33	Ubiquitin C-terminal Hydrolase-L1 Protects Cystic Fibrosis Transmembrane Conductance Regulator from Early Stages of Proteasomal Degradation. Journal of Biological Chemistry, 2010, 285, 11314-11325.	3.4	14
34	Applications of proteomic technologies for understanding the premature proteolysis of CFTR. Expert Review of Proteomics, 2010, 7, 473-486.	3.0	4
35	Transient effectiveness of vitamin D2 therapy in pediatric cystic fibrosis patients. Journal of Cystic Fibrosis, 2010, 9, 143-149.	0.7	28
36	Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19268-19273.	7.1	399

#	Article	IF	Citations
37	Pseudomonas aeruginosa: can studies in engineered cells tell us why is it such a problem in people with cystic fibrosis? Focus on â€œCystic fibrosis transmembrane conductance regulator and caveolin-1 regulate epithelial cell internalization of Pseudomonas aeruginosaâ€. American Journal of Physiology - Cell Physiology, 2009, 297, C235-C237.	4.6	4
38	Spiperone, identified through compound screening, activates calcium-dependent chloride secretion in the airway. American Journal of Physiology - Cell Physiology, 2009, 296, C131-C141.	4.6	13
39	NHLBI Training Workshop Report: The Vanishing Pediatric Pulmonary Investigator and Recommendations for Recovery. Lung, 2009, 187, 367-374.	3.3	9
40	The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials, 2009, 30, 2591-2597.	11.4	285
41	Proteome of synaptosomeâ€associated proteins in spinal cord dorsal horn after peripheral nerve injury. Proteomics, 2009, 9, 1241-1253.	2.2	43
42	CFTR Is a Negative Regulator of NFÎºB Mediated Innate Immune Response. PLoS ONE, 2009, 4, e4664.	2.5	149
43	Atypical Cystic Fibrosis and CFTR-Related Diseases. Clinical Reviews in Allergy and Immunology, 2008, 35, 116-123.	6.5	46
44	Pulmonary function in adolescents with ataxia telangiectasia. Pediatric Pulmonology, 2008, 43, 59-66.	2.0	35
45	Current Treatment Recommendations for Correcting Vitamin D Deficiency in Pediatric Patients with Cystic Fibrosis Are Inadequate. Journal of Pediatrics, 2008, 153, 554-559.e2.	1.8	62
46	Cystic fibrosis presenting as recurrent pancreatitis in a young child with a normal sweat test and pancreas divisum: a case report. Journal of Medical Case Reports, 2008, 2, 176.	0.8	10
47	Dietary supplement use in pediatric patients with cystic fibrosis. American Journal of Health-System Pharmacy, 2008, 65, 562-565.	1.0	5
48	Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2008, 295, L933-L940.	2.9	35
49	Chemical Rescue of c:workingBhatia,08-augasmbuploadj-elbm0001-0142F508-CFTR Mimics Genetic Repair in Cystic Fibrosis Bronchial Epithelial Cells. Molecular and Cellular Proteomics, 2008, 7, 1099-1110.	3.8	58
50	CHOP Transcription Factor Mediates IL-8 Signaling in Cystic Fibrosis Bronchial Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2008, 38, 176-184.	2.9	59
51	Cystic fibrosis and estrogens: a perfect storm. Journal of Clinical Investigation, 2008, 118, 3841-4.	8.2	38
52	Repeated Aerosolized AAV-CFTR for Treatment of Cystic Fibrosis: A Randomized Placebo-Controlled Phase 2B Trial. Human Gene Therapy, 2007, 18, 726-732.	2.7	239
53	Emerging drug treatments for cystic fibrosis. Expert Opinion on Emerging Drugs, 2007, 12, 329-336.	2.4	20
54	Patients with Mutations in GsÎ± Have Reduced Activation of a Downstream Target in Epithelial Tissues due to Haploinsufficiency. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3941-3948.	3.6	0

#	Article	IF	Citations
55	Levofloxacin Pharmacokinetics in Adult Cystic Fibrosis. Chest, 2007, 131, 796-802.	0.8	28
56	Cystic Fibrosis Transmembrane Regulator Protein Mutations. Paediatric Drugs, 2007, 9, 1-10.	3.1	34
57	Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatric Pulmonology, 2007, 42, 610-623.	2.0	88
58	Protein microarray platforms for clinical proteomics. Proteomics - Clinical Applications, 2007, 1, 934-952.	1.6	44
59	Multiple Molecular Chaperoneâ€mediated Pharmacologic Rescue of Î” F508â€CFTR from ERAD. FASEB Journal, 2007, 21, A420.	0.5	0
60	Membrane-associated heparan sulfate is not required for rAAV-2 infection of human respiratory epithelia. Virology Journal, 2006, 3, 29.	3.4	8
61	Pharmacoproteomics of 4-Phenylbutyrate-Treated IB3-1 Cystic Fibrosis Bronchial Epithelial Cells. Journal of Proteome Research, 2006, 5, 562-571.	3.7	54
62	Serum proteomic signature for cystic fibrosis using an antibody microarray platform. Molecular Genetics and Metabolism, 2006, 87, 303-310.	1.1	69
63	Genetics and Pathophysiology of Cystic Fibrosis. , 2006, , 848-860.		1
64	Acidic pH Hyperpolarizes Nasal Potential Difference. Pediatric Pulmonology, 2006, 41, 151-157.	2.0	7
65	Respiratory Epithelial Gene Expression in Patients with Mild and Severe Cystic Fibrosis Lung Disease. American Journal of Respiratory Cell and Molecular Biology, 2006, 35, 327-336.	2.9	80
66	Regulation of the ClC-2 Lung Epithelial Chloride Channel by Glycosylation of SP1. American Journal of Respiratory Cell and Molecular Biology, 2006, 34, 754-759.	2.9	23
67	Variants in mannose-binding lectin and tumour necrosis factor Â affect survival in cystic fibrosis. Journal of Medical Genetics, 2006, 44, 209-214.	3.2	35
68	De Novo Biosynthetic Profiling of High Abundance Proteins in Cystic Fibrosis Lung Epithelial Cells. Molecular and Cellular Proteomics, 2006, 5, 1628-1637.	3.8	44
69	Is It Go or NO Go for S-Nitrosylation Modification-Based Therapies of Cystic Fibrosis Transmembrane Regulator Trafficking?: Fig. 1.. Molecular Pharmacology, 2006, 70, 1155-1158.	2.3	6
70	Selective Inhibition of Endoplasmic Reticulum-associated Degradation Rescues Î”F508-Cystic Fibrosis Transmembrane Regulator and Suppresses Interleukin-8 Levels. Journal of Biological Chemistry, 2006, 281, 17369-17378.	3.4	151
71	Signalling Pathways Have Different Expression Profiles in Human Platelets Isolated from Men and Women.. Blood, 2006, 108, 1519-1519.	1.4	0
72	Down-regulation of IL-8 expression in human airway epithelial cells through helper-dependent adenoviral-mediated RNA interference. Cell Research, 2005, 15, 111-119.	12.0	27

#	Article	IF	Citations
73	Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study of Aerosolized Interferon Gamma-1b in Patients With Mild to Moderate Cystic Fibrosis Lung Disease. Pediatric Pulmonology, 2005, 39, 209-218.	2.0	55
74	Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: Results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatric Pulmonology, 2005, 39, 339-348.	2.0	92
75	Correlation Between DNA Transfer and Cystic Fibrosis Airway Epithelial Cell Correction After Recombinant Adeno-Associated Virus Serotype 2 Gene Therapy. Human Gene Therapy, 2005, 16, 921-928.	2.7	35
76	Correlation Between DNA Transfer and Cystic Fibrosis Airway Epithelial Cell Correction After Recombinant Adeno-Associated Virus Serotype 2 Gene Therapy. Human Gene Therapy, 2005, .	2.7	0
77	A Phase I Trial of Intranasal Moli1901 for Cystic Fibrosis. Chest, 2004, 125, 143-149.	0.8	64
78	Can Curcumin Cure Cystic Fibrosis?. New England Journal of Medicine, 2004, 351, 606-608.	27.0	34
79	Evaluation of Exposure and Health Care Worker Response to Nebulized Administration of tgAAVCF to Patients with Cystic Fibrosis. Annals of Occupational Hygiene, 2004, 48, 673-81.	1.9	12
80	Standardized procedure for measurement of nasal potential difference: An outcome measure in multicenter cystic fibrosis clinical trials. Pediatric Pulmonology, 2004, 37, 385-392.	2.0	91
81	Modulation of Î”F508 Cystic Fibrosis Transmembrane Regulator Trafficking and Function with 4-Phenylbutyrate and Flavonoids. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 351-357.	2.9	79
82	Repeated Adeno-Associated Virus Serotype 2 Aerosol-Mediated Cystic Fibrosis Transmembrane Regulator Gene Transfer to the Lungs of Patients With Cystic Fibrosis. Chest, 2004, 125, 509-521.	0.8	351
83	Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins. Physiological Genomics, 2004, 16, 204-211.	2.3	75
84	Effect of Adeno-Associated Virusâ€“Specific Immunoglobulin G in Human Amniotic Fluid on Gene Transfer. Human Gene Therapy, 2003, 14, 365-373.	2.7	8
85	Phase I Trial of Intranasal and Endobronchial Administration of a Recombinant Adeno-Associated Virus Serotype 2 (rAAV2)-CFTR Vector in Adult Cystic Fibrosis Patients: A Two-Part Clinical Study. Human Gene Therapy, 2003, 14, 1079-1088.	2.7	213
86	Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 841-849.	5.6	300
87	Inflammatory and Microbiologic Markers in Induced Sputum after Intravenous Antibiotics in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 1471-1475.	5.6	160
88	Modulation of Sp1 and Sp3 in Lung Epithelial Cells Regulates ClC-2 Chloride Channel Expression. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 499-505.	2.9	13
89	Emerging drug treatments for cystic fibrosis. Expert Opinion on Emerging Drugs, 2003, 8, 523-535.	2.4	12
90	A Multicenter Study of the Effect of Solution Temperature on Nasal Potential Difference Measurements*. Chest, 2003, 124, 482-489.	0.8	37

#	Article	IF	Citations
91	Protein Processing and Degradation in Pulmonary Health and Disease. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 642-645.	2.9	7
92	Evidence of CFTR Function in Cystic Fibrosis after Systemic Administration of 4-Phenylbutyrate. Molecular Therapy, 2002, 6, 119-126.	8.2	178
93	Variant Cystic Fibrosis Phenotypes in the Absence ofCFTRMutations. New England Journal of Medicine, 2002, 347, 401-407.	27.0	161
94	cis-Acting elements within CFTR 5â€²-flanking DNA are not sufficient to decrease gene expression in response to phorbol ester. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2002, 1576, 306-315.	2.4	0
95	Therapeutic approaches to repair defects in Î”F508 CFTR folding and cellular targeting. Advanced Drug Delivery Reviews, 2002, 54, 1395-1408.	13.7	46
96	Advances in the diagnosis of cystic fibrosis in infants. Journal of Pediatrics, 2001, 139, 345-346.	1.8	5
97	Induction of HSP70 promotes Î”F508 CFTR trafficking. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 281, L58-L68.	2.9	121
98	In Utero AAV-Mediated Gene Transfer to Rabbit Pulmonary Epithelium. Molecular Therapy, 2001, 4, 115-121.	8.2	50
99	Type I, II, III, IV, and V cystic fibrosis transmembrane conductance regulator defects and opportunities for therapy. Current Opinion in Pulmonary Medicine, 2000, 6, 521-529.	2.6	30
100	Pharmacologic restoration of Î±ÎF508 CFTR-mediated chloride current. Kidney International, 2000, 57, 832-837.	5.2	35
101	Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of Î”F508-CFTR. American Journal of Physiology - Cell Physiology, 2000, 278, C259-C267.	4.6	250
102	pH-regulated chloride secretion in fetal lung epithelia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 278, L1248-L1255.	2.9	60
103	Cystic Fibrosis Gene Therapy Trials and Tribulations. Molecular Therapy, 2000, 1, 5-6.	8.2	17
104	Targeting Aerosol Deposition in Patients With Cystic Fibrosis. Chest, 2000, 118, 1069-1076.	0.8	61
105	A simplified cyclic adenosine monophosphateâ€“mediated sweat rate test for quantitative measure of cystic fibrosis transmembrane regulator (CFTR) function. Journal of Pediatrics, 2000, 137, 849-855.	1.8	8
106	Perinatal regulation of the ClC-2 chloride channel in lung is mediated by Sp1 and Sp3. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 276, L614-L624.	2.9	20
107	Keratinocyte Growth Factor Stimulates CLC-2 Expression in Primary Fetal Rat Distal Lung Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 1999, 20, 842-847.	2.9	24
108	Novel pharmacologic therapies for cystic fibrosis. Journal of Clinical Investigation, 1999, 103, 447-452.	8.2	85

#	Article	IF	Citations
109	Cystic fibrosis. Lancet, The, 1998, 351, 277-282.	13.7	163
110	Use of protein repair therapy in the treatment of cystic fibrosis. Current Opinion in Pediatrics, 1998, 10, 250-255.	2.0	22
111	Computed Tomography (CT) Scan Findings of the Paranasal Sinuses in Cystic Fibrosis. American Journal of Rhinology & Allergy, 1995, 9, 277-280.	2.2	13
112	A1 Receptor Antagonist 8-Cyclopentyl-1,3-dipropylxanthine Selectively Activates Chloride Efflux from Human Epithelial and Mouse Fibroblast Cell Lines Expressing the Cystic Fibrosis Transmembrane Regulator .DELTA.F508 Mutation. Biochemistry, 1995, 34, 9079-9087.	2.5	57
113	Transmembrane Mutations Alter the Channel Characteristics of the Cystic Fibrosis Transmembrane Conductance Regulator Expressed in Xenopus Oocytes. Cellular Physiology and Biochemistry, 1994, 4, 10-18.	1.6	15
114	â€œBronchitisâ€•obliterans and prolonged transient hypogammaglobulinemia in a child. Pediatric Pulmonology, 1993, 16, 375-379.	2.0	6
115	Cystic Fibrosis Gene and Protein Expression during Fetal Lung Development. American Journal of Respiratory Cell and Molecular Biology, 1993, 8, 201-208.	2.9	56
116	Gene Expression from Adeno-associated Virus Vectors in Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 1992, 7, 349-356.	2.9	167
117	Effect of hypoxia on endothelin-1 production by pulmonary vascular endothelial cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 1992, 1134, 105-111.	4.1	25
118	Defective regulation of outwardly rectifying Clâ¯ channels by protein kinase A corrected by insertion of CFTR. Nature, 1992, 358, 581-584.	27.8	433
119	Gene transfer by lipofection in rabbit and human secretory epithelial cells. Pflugers Archiv European Journal of Physiology, 1989, 415, 198-203.	2.8	31